December 2016
-
Device developer and manufacturer Nemera has announced its acquisition of Insight Product Development, which will become the US office of Nemera’s “Insight Innovation Center.” The company’s other design center office is located in La Verpillière,… Read more . . .
-
AZTherapies has announced that former Dooner Laboratories and Muro Pharmaceuticals CEO George D. Behrakis has joined the company’s board of directors. Behrakis sold Dooner Laboratories, which manufactured theophylline products for asthma, to Rorer in 1977… Read more . . .
-
Alvogen has acquired marketing rights to the Alvesco cliclesonide metered dose inhaler in a number of Central and Eastern European (CEE) countries from Covis Pharma, the company said. Terms of the deal, which includes Bulgaria,… Read more . . .
-
Inhalation Sciences (ISAB) has announced that “a leading European inhaled pharmaceutical developer” has contracted with the company for a feasibility study using ISAB’s PreciseInhale aerosol generator with new nebulizer capabilities. The feasibility study is the… Read more . . .
-
The One Drop diabetes management platform has agreed to integrate MannKind’s BluHale inhaler monitoring device for the Afrezza insulin DPI, the companies said. The integration of the BluHale device will allow for monitoring of insulin… Read more . . .
-
Verona Pharma has announced that a Phase 2 trial of its RPL554 ensifentrine DPI for the treatment of COPD met all primary and secondary endpoints related to improvement in lung function. The company had previously… Read more . . .
-
AZ Therapies has announced that the Phase 3 COGNITE study of ALZT-OP1 inhaled cromolyn/oral ibuprofen for the treatment of early stage Alzheimer’s disease has completed enrollment. The company, which announced the initiation of the study… Read more . . .
-
Italfarmaco has announced that it will pay Neupharma “a total sum up to double digits in USD millions, excluding royalties” for an exclusive option to acquire global development and commercialization rights to inhaled teicoplanin for… Read more . . .
-
A spokesperson for Novartis has confirmed to OINDPnews that Mylan exercised an option to acquire a San Carlos, CA, USA manufacturing facility for TOBI inhaled tobramycin products in May 2019 and is expected to acquire… Read more . . .
-
Auris Medical has announced the initiation of the Phase 2 TRAVERS trial of its AM-125 intranasal betahistine for the treatment of acute vertigo resulting from removal of a vestibular schwannoma. Auris is also developing intranasal… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland